| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.05 | 0.3 |
| mRNA | BRD-K96970199 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.3 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.052 | 0.3 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.13 | 0.3 |